Featured Press Releases

Vaxxas begins a Phase I clinical trial for an H7N9 influenza vaccine using its high-density microarray patch (HD-MAP)

Vaxxas begins a Phase I clinical trial for an H7N9 influenza vaccine using its high-density microarray patch (HD-MAP)

Stealth BioTherapeutics announces an FDA advisory committee meeting to review Elamipretide for Barth syndrome treatment

Stealth BioTherapeutics announces an FDA advisory committee meeting to review Elamipretide for Barth syndrome treatment

  • 10 Sep 2024

Stealth BioTherapeutics Inc. a clinical-stage biotechnology company focused on the discovery,...

TIVDAK® Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

TIVDAK® Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

ADC Therapeutics shares promising initial LOTIS-7 trial data on ZYNLONTA® combined with a bispecific antibody for relapsed/refractory DLBCL.

ADC Therapeutics shares promising initial LOTIS-7 trial data on ZYNLONTA® combined with a bispecific antibody for relapsed/refractory DLBCL.

Ark Biopharmaceutical Granted China Marketing Authorization for Aizhida in ADHD Treatment

Ark Biopharmaceutical Granted China Marketing Authorization for Aizhida in ADHD Treatment

Neurophet gains FDA 510(k) clearance for Neurophet AQUA, advancing multiple sclerosis analysis with AI-driven precision

Neurophet gains FDA 510(k) clearance for Neurophet AQUA, advancing multiple sclerosis analysis with AI-driven precision

U.S. FDA Accepts sBLA for ENFLONSIA™ to Expand RSV Indication to High-Risk Children Under Two

U.S. FDA Accepts sBLA for ENFLONSIA™ to Expand RSV Indication to High-Risk Children Under Two

  • Merck & Co., Inc
  • 06 Aug 2026
Takeda

Takeda's ORZEYFUL™ Receives U.S. FDA Approval for Narcolepsy Type 1

  • Takeda Pharmaceutical Company Limited
  • 05 Aug 2026
Why the Pharmacy System Rewards the Wrong Results: It Is Working as Designed

Why the Pharmacy System Rewards the Wrong Results: It Is Working as Designed

  • SHARx
  • 04 Aug 2026
Triquetra Health Launched BioActive Vitamin B1™—the First Complete B1 Activation System with a 600 mg Research-Matched Dose and Full Cofactor Support

Triquetra Health Launched BioActive Vitamin B1™—the First Complete B1 Activation System with a 600 mg Research-Matched Dose and Full Cofactor Support

  • Triquetra Health LLC
  • 03 Aug 2026
Dallas-Based Microbiome Brand resbiotic® Comes Home to Texas with Launch at H-E-B

Dallas-Based Microbiome Brand resbiotic® Comes Home to Texas with Launch at H-E-B

  • Resbiotic Nutrition, Inc.
  • 03 Aug 2026
US Capital Global Securities Announces $20 Million Offering for Thplasma to Invest in the Future of Plasma Therapeutics

US Capital Global Securities Announces $20 Million Offering for Thplasma to Invest in the Future of Plasma Therapeutics

  • US Capital Global
  • 03 Aug 2026

Most Popular
August   2026
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31            

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.